Form 4: Integra LifeSciences Exec's RSU Vesting & Tax Sale

Harvinder Singh, EVP & President, International at Integra LifeSciences, reported the vesting of 11,965 restricted stock units and a subsequent sale of 3,281 shares for tax obligations.

Summary

• Harvinder Singh, EVP & President, International of Integra LifeSciences Holdings Corp (IART), reported changes in beneficial ownership.
• On October 12, 2025, 11,965 restricted stock units (RSUs) vested in full, converting into common stock.
• These RSUs were granted on October 12, 2022, and vested on their third anniversary.
• Following the vesting, 3,281 shares of common stock were disposed of at a price of $13.34 per share to satisfy tax withholding obligations.
• The reporting person retained 8,684 shares from the vested RSUs.
• After these transactions, Harvinder Singh beneficially owns 21,936 shares of common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine, pre-scheduled compensation event (RSU vesting) for a key executive, which is generally a positive sign of executive retention and alignment. The associated tax sale is a standard practice and not indicative of negative sentiment.

Positives

• The vesting of 11,965 restricted stock units indicates the successful fulfillment of a long-term incentive compensation plan for a key executive.
• The executive retained 8,684 shares from the vesting, increasing their direct ownership in the company.

Negatives

• A total of 3,281 shares were sold to cover tax liabilities, representing a reduction in the executive's direct ownership, although this is a common practice for RSU vesting.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction represents a routine insider compensation event, common across publicly traded companies where executives receive equity-based awards that vest over time. It does not reflect broader industry trends or competitive shifts.

Stakeholder Impact

• Shareholders: This is a routine insider transaction and is unlikely to have a significant direct impact on the company's share price or fundamental value. It demonstrates the ongoing operation of executive compensation plans.
• Employees: The vesting of RSUs for a senior executive reinforces the company's equity compensation structure and may serve as an example of long-term incentive payouts.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. It does not provide new material information that would alter the fundamental investment thesis for Integra LifeSciences Holdings Corp. Investors should continue to evaluate the company based on its operational performance, financial results, and strategic outlook, rather than this standard insider transaction.

Keywords

IART, Integra LifeSciences, Harvinder Singh, Form 4, Restricted Stock Units, RSU Vesting, Insider Transaction, Stock Ownership, Tax Withholding